Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.

Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, Rickert M, Holz C, Aschenbrenner L, Yang AH, Kraynov E, Evering W, Obert L, Lee C, Sai T, Mistry T, Lindquist KC, Van Blarcom T, Strop P, Chaparro-Riggers J, Liu SH.

Sci Rep. 2019 Jun 10;9(1):8420. doi: 10.1038/s41598-019-44874-0.

2.

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.

Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J, Salek-Ardakani S, Kraynov E.

J Immunother Cancer. 2019 Apr 15;7(1):105. doi: 10.1186/s40425-019-0586-0. Review.

3.

RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.

Strop P, Tran TT, Dorywalska M, Delaria K, Dushin R, Wong OK, Ho WH, Zhou D, Wu A, Kraynov E, Aschenbrenner L, Han B, O'Donnell CJ, Pons J, Rajpal A, Shelton DL, Liu SH.

Mol Cancer Ther. 2016 Nov;15(11):2698-2708. Epub 2016 Aug 31.

4.

Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.

Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, Datta-Mannan A, Sriraman P, Bairlein M, Yang JJ, Barfield M, Xiao G, Escandon E, Wang W, Rock DA, Chemuturi NV, Moore DJ.

Drug Metab Dispos. 2016 May;44(5):617-23. doi: 10.1124/dmd.115.068049. Epub 2015 Dec 15. Review.

PMID:
26669328
5.

Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development.

Campion SN, Han B, Cappon GD, Lewis EM, Kraynov E, Liang H, Bowman CJ.

Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70. doi: 10.1016/j.yrtph.2015.08.007. Epub 2015 Sep 14.

PMID:
26382609
6.

Receptor occupancy and blocking of STAT5 signaling by an anti-IL-7 receptor α antibody in cynomolgus monkeys.

Kern B, Li W, Bono C, Lee LF, Kraynov E.

Cytometry B Clin Cytom. 2016 Mar;90(2):191-8. doi: 10.1002/cyto.b.21247. Epub 2015 May 27.

7.

Structure-based design of novel human Pin1 inhibitors (III): optimizing affinity beyond the phosphate recognition pocket.

Guo C, Hou X, Dong L, Marakovits J, Greasley S, Dagostino E, Ferre R, Johnson MC, Humphries PS, Li H, Paderes GD, Piraino J, Kraynov E, Murray BW.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4187-91. doi: 10.1016/j.bmcl.2014.07.044. Epub 2014 Jul 22.

PMID:
25091930
8.

A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

Chen X, Hickling T, Kraynov E, Kuang B, Parng C, Vicini P.

AAPS J. 2013 Oct;15(4):1141-54. doi: 10.1208/s12248-013-9517-z. Epub 2013 Aug 30.

9.

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.

Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L.

Drug Metab Dispos. 2013 Sep;41(9):1598-609. doi: 10.1124/dmd.113.052225. Epub 2013 Jun 21. Review.

PMID:
23792813
10.

Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.

Luu KT, Kraynov E, Kuang B, Vicini P, Zhong WZ.

AAPS J. 2013 Apr;15(2):551-8. doi: 10.1208/s12248-013-9464-8. Epub 2013 Feb 14. Review.

11.

Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.

Qiu M, Peng Q, Jiang I, Carroll C, Han G, Rymer I, Lippincott J, Zachwieja J, Gajiwala K, Kraynov E, Thibault S, Stone D, Gao Y, Sofia S, Gallo J, Li G, Yang J, Li K, Wei P.

Cancer Lett. 2013 Jan 28;328(2):261-70. doi: 10.1016/j.canlet.2012.09.023. Epub 2012 Oct 3.

PMID:
23041621
12.

Discovery of pyrroloaminopyrazoles as novel PAK inhibitors.

Guo C, McAlpine I, Zhang J, Knighton DD, Kephart S, Johnson MC, Li H, Bouzida D, Yang A, Dong L, Marakovits J, Tikhe J, Richardson P, Guo LC, Kania R, Edwards MP, Kraynov E, Christensen J, Piraino J, Lee J, Dagostino E, Del-Carmen C, Deng YL, Smeal T, Murray BW.

J Med Chem. 2012 May 24;55(10):4728-39. doi: 10.1021/jm300204j. Epub 2012 May 14.

PMID:
22554206
13.

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.

Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E.

J Exp Clin Cancer Res. 2012 Mar 23;31:26. doi: 10.1186/1756-9966-31-26.

14.

A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.

Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E.

J Pharmacol Exp Ther. 2012 Jun;341(3):702-8. doi: 10.1124/jpet.112.191999. Epub 2012 Mar 13.

PMID:
22414855
15.

Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.

Wu J, Pungaliya P, Kraynov E, Bates B.

Biomarkers. 2012 Mar;17(2):125-33. doi: 10.3109/1354750X.2011.643485. Epub 2011 Dec 22.

PMID:
22188260
16.

How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential.

Kraynov E, Martin SW, Hurst S, Fahmi OA, Dowty M, Cronenberger C, Loi CM, Kuang B, Fields O, Fountain S, Awwad M, Wang D.

Drug Metab Dispos. 2011 Oct;39(10):1779-83. doi: 10.1124/dmd.111.040808. Epub 2011 Jul 18. Review.

PMID:
21768274
17.

PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.

Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes K, Christensen JG, VanArsdale T.

Clin Cancer Res. 2010 Nov 1;16(21):5177-88. doi: 10.1158/1078-0432.CCR-10-1343. Epub 2010 Sep 9.

18.

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.

Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager M, Kraynov E, Popoff I, Christensen JG, Martinez R, Kephart SE, Marakovits J, Karlicek S, Bergqvist S, Smeal T.

Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. doi: 10.1073/pnas.0911863107. Epub 2010 May 3.

19.

Structure-based design of novel human Pin1 inhibitors (II).

Dong L, Marakovits J, Hou X, Guo C, Greasley S, Dagostino E, Ferre R, Johnson MC, Kraynov E, Thomson J, Pathak V, Murray BW.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4. doi: 10.1016/j.bmcl.2010.02.033. Epub 2010 Feb 14.

PMID:
20207139
20.

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.

Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O'Connor P, Anderes K.

Mol Cancer Ther. 2008 Aug;7(8):2394-404. doi: 10.1158/1535-7163.MCT-07-2391.

21.

Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.

Li H, Anderes KL, Kraynov EA, Luthin DR, Do QQ, Hong Y, Tompkins E, Sun ET, Rajapakse R, Pathak VP, Christie LC, Feng J, Vazir H, Castillo R, Gregory ML, Castro M, Nared-Hood K, Paderes G, Anderson MB.

J Med Chem. 2006 Jun 1;49(11):3362-7. Erratum in: J Med Chem. 2006 Sep 21;49(19):5849. Feng, Jun [added].

PMID:
16722655
22.

Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats.

Anderes KL, Luthin DR, Castillo R, Kraynov EA, Castro M, Nared-Hood K, Gregory ML, Pathak VP, Christie LC, Paderes G, Vazir H, Ye Q, Anderson MB, May JM.

J Pharmacol Exp Ther. 2003 May;305(2):688-95. Epub 2003 Jan 24.

PMID:
12606616
23.

Characterization of mono- and diaminopyrimidine derivatives as novel, nonpeptide gonadotropin releasing hormone (GnRH) receptor antagonists.

Luthin DR, Hong Y, Tompkins E, Anderes KL, Paderes G, Kraynov EA, Castro MA, Nared-Hood KD, Castillo R, Gregory M, Vazir H, May JM, Anderson MB.

Bioorg Med Chem Lett. 2002 Dec 16;12(24):3635-9.

PMID:
12443792

Supplemental Content

Loading ...
Support Center